# Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

> **NCT05220267** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 43 (estimated)

## Conditions studied

- Non Clear Cell Renal Carcinoma

## Interventions

- **DRUG:** Anlotinib plus Sintilimab

## Key facts

- **NCT ID:** NCT05220267
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-28
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220267, "Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05220267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*